Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2757138 | 0.84 | — | — | |
| SCHEMBL23773240 | 0.84 | CYP2C9 (0.38) | CYP2C9TSHRCYP2C19TDP1 | |
| SCHEMBL21115556 | 0.84 | CYP2C9 (0.38) | CYP2C9TSHRCYP2C19TDP1 | |
| SCHEMBL356705 | 0.84 | CYP2C9 (0.38) | CYP2C9TSHRCYP2C19TDP1 | |
| SCHEMBL21882657 | 0.81 | CYP2C9 (0.52) | CYP2C9TSHRCYP2C19TDP1 | |
| SCHEMBL22080094 | 0.78 | DPP4 (0.33) | CYP2C9TSHRCYP2C19TDP1 | |
| SCHEMBL19578736 | 0.78 | CYP2C9 (0.48) | CYP2C9TSHRCYP2C19TDP1 | |
| Nanofin SCHEMBL83612 | 0.74 | — | — | |
| Nanofin SCHEMBL24269496 | 0.74 | — | — | |
| Nanofin SCHEMBL25816 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013177292-A1 | TITANIUM-CONTAINING PRECURSORS FOR VAPOR DEPOSITION | L'AIR LIQUIDE, SOCIETE ANONYME POUR L'ETUDE ET L'EXPLOITATION DES PROCEDES GEORGES CLAUDE (FR) | 2013-11-28 | — | — | WO | claimed |
| WO-2013177269-A2 | ZIRCONIUM-CONTAINING PRECURSORS FOR VAPOR DEPOSITION | L'AIR LIQUIDE, SOCIETE ANONYME POUR L'ETUDE ET L'EXPLOITATION DES PROCEDES GEORGES CLAUDE (FR) | 2013-11-28 | — | — | WO | claimed |
| WO-2013177284-A1 | HAFNIUM-CONTAINING PRECURSORS FOR VAPOR DEPOSITION | L'AIR LIQUIDE, SOCIETE ANONYME POUR L'ETUDE ET L'EXPLOITATION DES PROCEDES GEORGES CLAUDE (FR) | 2013-11-28 | — | — | WO | claimed |
| US-20230346942-A1 | MACROMOLECULAR PRODRUGS FOR LIGHT-EMITTING DIODES AND USES THEREOF | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2023-11-02 | — | — | US | disclosed |
| WO-2023116934-A1 | KRASG12D PROTEIN HYDROLYSIS REGULATOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 苏州泽璟生物制药股份有限公司 | 2023-06-29 | — | — | WO | disclosed |
| US-20230183240-A9 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-06-15 | — | — | US | disclosed |
| WO-2023011533-A1 | COMPOSITIONS AND METHODS OF COMBINATION THERAPY FOR TARGETING LYMPHOMA | CULLGEN (SHANGHAI) , INC. (CN) | 2023-02-09 | — | — | WO | disclosed |
| WO-2022068933-A1 | COMPOUNDS AND METHODS OF TREATING DISEASES | CULLGEN (SHANGHAI) , INC. (CN) | 2022-04-07 | — | — | WO | disclosed |
| US-20210199672-A1 | BIOMARKERS AND METHODS FOR EVALUATION AND TREATMENT OF EPILEPTIC VS NON-EPILEPTIC SEIZURES / NO SEIZURES / PSYCHOGENIC NON-EPILEPTIC SEIZURES | EVOGEN, INC. (US) | 2021-07-01 | — | — | US | disclosed |
| US-10975055-B2 | Inhibitors of interleukin-1 receptor-associated kinases and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-04-13 | — | — | US | disclosed |
| US-10947237-B2 | Antimicrobial compounds and methods of making and using the same | BioVersys AG (CH) | 2021-03-16 | — | — | US | disclosed |
| WO-2019164880-A1 | ANTIMICROBIALS AND METHODS OF MAKING AND USING SAME | DUFFY ERIN M (US) | 2019-08-29 | — | — | WO | disclosed |
| US-20190119301-A1 | THIAZOLYL-CONTAINING COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-04-25 | — | — | US | disclosed |
| US-20180110778-A1 | 4,6-PYRIMIDINYLENE DERIVATIVES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-04-26 | — | — | US | disclosed |
| WO-2017193017-A1 | ANTIMICROBIALS AND METHODS OF MAKING AND USING SAME | MELINTA THERAPEUTICS, INC. (US) | 2017-11-09 | — | — | WO | disclosed |
| WO-2017193016-A1 | ANTIMICROBIALS AND METHODS OF MAKING AND USING SAME | MELINTA THERAPEUTICS, INC. (US) | 2017-11-09 | — | — | WO | disclosed |
| WO-2013177292-A1 | TITANIUM-CONTAINING PRECURSORS FOR VAPOR DEPOSITION | L'AIR LIQUIDE, SOCIETE ANONYME POUR L'ETUDE ET L'EXPLOITATION DES PROCEDES GEORGES CLAUDE (FR) | 2013-11-28 | — | — | WO | disclosed |
| WO-2013177284-A1 | HAFNIUM-CONTAINING PRECURSORS FOR VAPOR DEPOSITION | L'AIR LIQUIDE, SOCIETE ANONYME POUR L'ETUDE ET L'EXPLOITATION DES PROCEDES GEORGES CLAUDE (FR) | 2013-11-28 | — | — | WO | disclosed |
| WO-2013177269-A2 | ZIRCONIUM-CONTAINING PRECURSORS FOR VAPOR DEPOSITION | L'AIR LIQUIDE, SOCIETE ANONYME POUR L'ETUDE ET L'EXPLOITATION DES PROCEDES GEORGES CLAUDE (FR) | 2013-11-28 | — | — | WO | disclosed |
| EP-0015763-B1 | ZIEGLER TYPE CATALYST SYSTEM | EXXON RESEARCH AND ENGINEERING COMPANY (US) | 1984-05-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190119301-A1 | THIAZOLYL-CONTAINING COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES | BTK, BCL9L, BCL9 | CYP2C9 4176/4885TSHR 2001/4885CYP2C19 4339/4885 |
| US-20180110778-A1 | 4,6-PYRIMIDINYLENE DERIVATIVES AND USES THEREOF | CDKL4, CDKL5, PIP5K1A | CYP2C9 1285/4885TSHR 3495/4885CYP2C19 1455/4885 |
| US-10975055-B2 | Inhibitors of interleukin-1 receptor-associated kinases and uses thereof | IRAK1, IRAK4, IRAK2 | CYP2C9 1261/4885TSHR 2248/4885CYP2C19 1481/4885 |
| US-20230183240-A9 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | CDK3, CDK13, CDK1 | CYP2C9 805/4885TSHR 3325/4885CYP2C19 927/4885 |
| US-10947237-B2 | Antimicrobial compounds and methods of making and using the same | LPO, MPO, CAT | CYP2C9 1956/4885TSHR 4406/4885CYP2C19 1662/4885 |
| US-20230346942-A1 | MACROMOLECULAR PRODRUGS FOR LIGHT-EMITTING DIODES AND USES THEREOF | CRY1, MAPT, PYGL | CYP2C9 11/4885TSHR 4119/4885CYP2C19 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.